Literature DB >> 22738077

A population-based audit of the clinical use of faecal occult blood testing in primary care for colorectal cancer.

A Gillberg1, E Ericsson, F Granstrom, L I Olsson.   

Abstract

AIM: Symptoms related to colorectal cancer (CRC) are common. We investigated the value of the faecal occult blood test (FOBT), when administered in primary care, in the diagnosis of CRC.
METHOD: All patients who underwent a FOBT (Hemoccult II) at 20 public primary care centres in Sörmland County, Sweden, during 2000-2005, were included (n=9048). Linkage to the Swedish Cancer Registry identified all cases of CRC. Symptoms recorded at the time of the FOBT were retrieved from the patient records. The outcome from the FOBT to diagnosis and subsequent survival was compared between patients who were FOBT negative and patients who were FOBT positive.
RESULTS: One-hundred and sixty-one patients were diagnosed with CRC within 2 years after undergoing a FOBT in primary care. These comprised 18% of all 917 patients diagnosed with CRC in the county during the study period. In 41 (25.4%) of the 161 patients the test was negative. Symptoms related to CRC were documented for 158 (98%) patients at the time the FOBT was administered. The median investigation time from the FOBT test to the diagnosis of CRC was 91 days: 80 days for FOBT-positive patients and 188 days for FOBT-negative patients (P<0.001). This difference was significant independent of age, sex and site of tumour. The hazard ratio for FOBT negativity, 3 years after the FOBT, when adjusted for age and sex, was 1.47 (95% CI, 0.81-2.68).
CONCLUSION: Despite having suggestive symptoms, 41 (4.5%) of 917 CRC patients had a negative FOBT result in primary care. This was associated with diagnostic delay and, potentially, a worse outcome.
© 2012 The Authors. Colorectal Disease © 2012 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Mesh:

Year:  2012        PMID: 22738077     DOI: 10.1111/j.1463-1318.2012.03149.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  7 in total

1.  Low-risk bowel cancer symptoms: is it time for FIT?

Authors:  Mazlan Kamarudin
Journal:  Br J Gen Pract       Date:  2019-07       Impact factor: 5.386

2.  Faecal immunochemical testing in general practice.

Authors:  Nigel D'Souza; Anthony Brzezicki; Muti Abulafi
Journal:  Br J Gen Pract       Date:  2019-02       Impact factor: 5.386

3.  Results of National Colorectal Cancer Screening Program in Croatia (2007-2011).

Authors:  Miroslava Katičić; Nataša Antoljak; Milan Kujundžić; Valerija Stamenić; Dunja Skoko Poljak; Danica Kramarić; Davor Stimac; Marija Strnad Pešikan; Mirko Samija; Zdravko Ebling
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

4.  Implementation of immunochemical faecal occult blood test in general practice: a study protocol using a cluster-randomised stepped-wedge design.

Authors:  Jakob Søgaard Juul; Flemming Bro; Nete Hornung; Berit Sanne Andersen; Søren Laurberg; Frede Olesen; Peter Vedsted
Journal:  BMC Cancer       Date:  2016-07-11       Impact factor: 4.430

5.  Could it be colorectal cancer? General practitioners' use of the faecal occult blood test and decision making--a qualitative study.

Authors:  Cecilia Högberg; Eva Samuelsson; Mikael Lilja; Eva Fhärm
Journal:  BMC Fam Pract       Date:  2015-10-26       Impact factor: 2.497

6.  Immunochemical faecal occult blood tests in primary care and the risk of delay in the diagnosis of colorectal cancer.

Authors:  Cecilia Högberg; Pontus Karling; Jörgen Rutegård; Mikael Lilja; Thomas Ljung
Journal:  Scand J Prim Health Care       Date:  2013-11-06       Impact factor: 2.581

Review 7.  Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance.

Authors:  Marie Westwood; Shona Lang; Nigel Armstrong; Sietze van Turenhout; Joaquín Cubiella; Lisa Stirk; Isaac Corro Ramos; Marianne Luyendijk; Remziye Zaim; Jos Kleijnen; Callum G Fraser
Journal:  BMC Med       Date:  2017-10-24       Impact factor: 8.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.